Xiaodong Chen
Xiaodong Chen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anqing Chen
State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Chengdu University of Technology, Chengdu, China
1 shared publication - Chao Ma
National University of Defense Technology
1 shared publication Chen Jiayan
Wenzhou Key Laboratory of Sanitary Microbiology, Wenzhou Medical University
1 shared publicationCongyu Yu
State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation & Institute of Sedimentary Geology & College of Computer Science and Cyber Security, Chengdu University of Technology, Chengdu 610059, China
1 shared publication- Donghao Zheng
Department of Geosciences Princeton University Princeton NJ USA
1 shared publication Gelin Xu
Department of Neurology, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu Province, 210002, China
1 shared publication
Latest Publications
- Open Access
- 5 August 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0017825
Clostridium butyricum enhances cognitive function in APP/PS1 mice by modulating neuropathology and regulating acetic acid levels in the gut microbiota
The amyloid deposition-to-cognitive impairment pathway is crucial in Alzheimer’s disease (AD) pathogenesis, with gut microbes influencing its development. Our study evaluated Clostridium butyricum MIYAIRI 588 (CBM588) as a potential AD treatment. In APP/PS1 mice, CBM588 improved cognitive function and alleviated colonic tissue pathology by modulating tight junction proteins (upregulating Claudin 1, ZO-1, and Occludin) and reducing inflammatory cytokines (IL-6, IL-1β, and TNF-α mRNA). It also reduced Aβ plaque deposition in the brain, regulated the JNK/CDK5/GSK-3β pathway to inhibit Tau hyperphosphorylation, and maintained neuronal integrity by downregulating Bax/Bcl-2 and inflammatory cytokines, thereby inhibiting apoptosis. While not altering the overall gut flora structure, CBM588 increased acetate-producing bacteria and decreased pro-inflammatory genera, reducing lipopolysaccharide levels. It also elevated short-chain fatty acids, particularly acetate, in colonic feces and brain tissue. Sodium acetate further inhibited BV2 cell apoptosis by suppressing JAK/STAT signaling and reducing Aβ and p-Tau expressions. In conclusion, CBM588 holds great potential as a novel probiotic for AD control. IMPORTANCE: The current study underscores the pivotal role of gut microbiota modulation in the treatment of Alzheimer’s disease(AD). Our comprehensive evaluation of CBM588 demonstrates its remarkable potential to ameliorate cognitive impairment in APP/PS1 mice by modulating gut microbiota composition, upregulating short-chain fatty acids, particularly acetate, and mitigating neuroinflammation. These findings not only provide novel insights into the gut-brain axis in AD but also offer a promising therapeutic strategy, highlighting the importance of targeting gut microbiota in future AD research and interventions.
- 5 August 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0017825
Open AccessClostridium butyricum enhances cognitive function in APP/PS1 mice by modulating neuropathology and regulating acetic acid levels in the gut microbiota
The amyloid deposition-to-cognitive impairment pathway is crucial in Alzheimer’s disease (AD) pathogenesis, with gut microbes influencing its development. Our study evaluated Clostridium butyricum MIYAIRI 588 (CBM588) as a potential AD treatment. In APP/PS1 mice, CBM588 improved cognitive function and alleviated colonic tissue pathology by modulating tight junction proteins (upregulating Claudin 1, ZO-1, and Occludin) and reducing inflammatory cytokines (IL-6, IL-1β, and TNF-α mRNA). It also reduced Aβ plaque deposition in the brain, regulated the JNK/CDK5/GSK-3β pathway to inhibit Tau hyperphosphorylation, and maintained neuronal integrity by downregulating Bax/Bcl-2 and inflammatory cytokines, thereby inhibiting apoptosis. While not altering the overall gut flora structure, CBM588 increased acetate-producing bacteria and decreased pro-inflammatory genera, reducing lipopolysaccharide levels. It also elevated short-chain fatty acids, particularly acetate, in colonic feces and brain tissue. Sodium acetate further inhibited BV2 cell apoptosis by suppressing JAK/STAT signaling and reducing Aβ and p-Tau expressions. In conclusion, CBM588 holds great potential as a novel probiotic for AD control. IMPORTANCE: The current study underscores the pivotal role of gut microbiota modulation in the treatment of Alzheimer’s disease(AD). Our comprehensive evaluation of CBM588 demonstrates its remarkable potential to ameliorate cognitive impairment in APP/PS1 mice by modulating gut microbiota composition, upregulating short-chain fatty acids, particularly acetate, and mitigating neuroinflammation. These findings not only provide novel insights into the gut-brain axis in AD but also offer a promising therapeutic strategy, highlighting the importance of targeting gut microbiota in future AD research and interventions.
- 21 January 2024
- Published by Elsevier in Geoenergy Science and Engineering
- Vol. 234, 212662
DDViT: Advancing lithology identification on FMI image logs through a dual modal transformer model with less information drop
- 21 January 2024
- Published by Elsevier in Geoenergy Science and Engineering
- Vol. 234, 212662
DDViT: Advancing lithology identification on FMI image logs through a dual modal transformer model with less information drop
- 7 November 2017
- Published by Springer Nature in Neurological Sciences
- Vol. 39 (1) , 155-159
Intravenous thrombolysis in SLE-related stroke: a case report and literature review
Patients with systemic lupus erythematosus (SLE) bear an increased risk of ischemic stroke. However, evidences for treating acute stroke due to artery thrombosis in SLE patients are extremely limited. A 45-year-old woman experienced sudden left hemiplegia. She was transported to the emergency department of our hospital 2 hours after the initial symptom. According to the medical records, the patient was diagnosed with SLE at the age of 28. CT scanned 150 min after the initial symptom showed no evidence of acute changes or hemorrhage. Magnetic resonance angiography (MRA) revealed occlusion of the right proximal middle cerebral artery (MCA). Ischemic stroke was diagnosed and NIHSS scored 11. The occluded MCA was successfully recanalized with intravenous rtPA. Sequent vascular imaging and serological results indicated that the etiology of the occlusion in right MCA was SLE vasculitis. The patient attained a mRS of 3 at the 3-month follow-up. The case is the first one in the literature that acute ischemic stroke related to SLE vasculitis was treated successfully with intravenous rtPA thrombolysis. The feasibility of intravenous thrombolysis for stroke related to SLE warrant further study.
- 7 November 2017
- Published by Springer Nature in Neurological Sciences
- Vol. 39 (1) , 155-159
Intravenous thrombolysis in SLE-related stroke: a case report and literature review
Patients with systemic lupus erythematosus (SLE) bear an increased risk of ischemic stroke. However, evidences for treating acute stroke due to artery thrombosis in SLE patients are extremely limited. A 45-year-old woman experienced sudden left hemiplegia. She was transported to the emergency department of our hospital 2 hours after the initial symptom. According to the medical records, the patient was diagnosed with SLE at the age of 28. CT scanned 150 min after the initial symptom showed no evidence of acute changes or hemorrhage. Magnetic resonance angiography (MRA) revealed occlusion of the right proximal middle cerebral artery (MCA). Ischemic stroke was diagnosed and NIHSS scored 11. The occluded MCA was successfully recanalized with intravenous rtPA. Sequent vascular imaging and serological results indicated that the etiology of the occlusion in right MCA was SLE vasculitis. The patient attained a mRS of 3 at the 3-month follow-up. The case is the first one in the literature that acute ischemic stroke related to SLE vasculitis was treated successfully with intravenous rtPA thrombolysis. The feasibility of intravenous thrombolysis for stroke related to SLE warrant further study.
- 16 May 2017
- Published by Springer Nature in Neurological Sciences
- Vol. 10 (9) , 537-1720
Guillain–Barré syndrome variant with facial diplegia and paresthesias after reactivation of varicella zoster virus
- 16 May 2017
- Published by Springer Nature in Neurological Sciences
- Vol. 10 (9) , 537-1720
Guillain–Barré syndrome variant with facial diplegia and paresthesias after reactivation of varicella zoster virus